Healthy pipeline for cancer treatments: PhRMA

Share this article:
A report delivered by industry trade group PhRMA has found a record 750 potential cancer treatments in the US research pipeline, according to a statement.

The report was released in Baton Rouge, LA, where it had “particular relevance,” according to PhRMA senior vice president Ken Johnnson. “According to the Centers for Disease Control and Prevention, Louisiana has the highest death rate from cancer in the United States,” said Johnson.  

Billy Tauzin, PhRMA president, CEO and formerly a US Representative of Louisiana's 3rd congressional district, noted the strong commitment by America's pharmaceutical research companies. “The medicines now in the research pipeline will add to the substantial progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments,” he said.

Among cancer treatments in the pipeline, 113 are for lung cancer, 90 for breast cancer, 65 for colorectal cancer and 88 for prostate cancer, according to a statement. 

In 2008, it is estimated that 294,120 men and 271,530 women will die from cancer in the US, according to the American Cancer Society.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...